Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Company Recalls Various Products Due To Potential Salmonella Contamination
Plainview Milk Products Cooperative, Plainview, Minn., is voluntarily recalling instant nonfat dried milk, whey protein, fruit stabilizers, and gums (thickening agents) that it has manufactured over the past two years, because they might be contaminated with Salmonella. The company sells these products to other industry customers, including distributors and manufacturers, who may have incorporated them into their own products. None of Plainview"s products were sold directly to the public.

HearAtLast To Launch Exclusive Groundbreaking Neuro-CompensatorTM Technology Hearing Aids From VitaSound
HearAtLast Holdings, Inc. (PINKSHEETS: HRAL), a leading provider of suitable affordable solutions to clients with hearing needs in the billion dollar hearing loss market, announced that in keeping with its tradition of bringing innovative new products to consumers, the Company announces the unveiling of breakthrough hearing products based on the Neuro-Compensator™ algorithm technology from VitaSound Audio.
News of the day
Test Detects Molecular Marker Of Aging In Humans
In 2004, researchers at the University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center announced a crucial discovery in the understanding of cellular aging. They found that as cells and tissues age, the expression of a key protein, called p16INK4a, dramatically increases in most mammalian organs. Because p16INK4a is a tumor suppressor protein, cancer researchers are interested in its role in cellular aging and cancer prevention.
Endocrinology

NICE Welcomes Office For Life Sciences New Blueprint To Support Innovative Drugs

NICE today welcomed the Office for Life Sciences new Blueprint to support the life sciences industry, which will also improve patient access to innovative new drugs. Welcoming the Blueprint launch, Andrew Dillon Chief Executive of NICE said: "Securing a successful future for the life sciences industries is important for patients and the UK economy.The Innovation Pass is an opportunity for data to be gathered on potentially important new treatments. NICE has been involved in discussions about the Innovation Pass, and we are looking forward to continuing to play a key role in developing the pass." Mr Dillon continued: "NICE is committed to engaging constructively with the pharmaceutical industry and we are extending the access that companies have to us, as we appraise their products. Later this year, we will begin asking pharmaceutical and other life sciences companies, whose products we are evaluating, to make technical staff available to engage with our advisory Appraisal Committees. They will be able to respond to requests from committee chairs to clarify the data they have submitted and to point out any error of fact in the presentation of their data. We believe that this will give companies more confidence in the way NICE handles the evaluation of their products." NICE


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009